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ABSTRACT 
 
The production of recombinant transmembrane proteins is due to their biochemical properties 
often troublesome and time consuming. Here the prokaryotic expression and purification of 
the transmembrane envelope proteins of the feline and primate foamy virus using a screening 
assay for optimisation of expression in 96 deep well plates is described. Testing 
simultaneously various bacterial strains, media, temperatures, inducer concentrations and 
different transformants, conditions for an about twentyfold increased production were 
quickly determined. These small scale test conditions could be easily scaled up, allowing 
purification of milligram amounts of recombinant protein. Proteins with a purity of about 
95% were produced using a new purification protocols, they were characterised by gel 
filtration and circular dichroism and successfully applied in immunological assays screening 
for foamy virus infection and in immunisation studies. Compared to the previously described 
protocol (Muehle et al., Virology, 412:333-340, 2011), proteins with similar characteristics 
but about thirtyfold increased yields were obtained. The screening and production method 
presented here can also be applied for the production of transmembrane envelope proteins of 
other retroviruses, including HIV-1.  
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Abbreviations used: CDNB, 1-chloro-2,4-dinitrobenzene; DDM, n-dodecyl-ß-maltoside; 
IPTG, isopropyl β-D-1-thiogalactopyranoside; OPD, o-phenylenediamine 
dihydrochloride; TM protein, transmembrane envelope protein 
 
Introduction 
Technologies for the production and purification of recombinant proteins have been 
greatly improved in the last years and contributed significantly to the increase of 
knowledge in the field of proteomics [1]. Although several commercial expression 
systems are available, establishing an efficient expression and purification protocol for a 
new protein is still rather cumbersome. Expression in E. coli is a preferred cheap and 
easy to handle method for small and large scale production [2, 3]. However, when 
dealing with proteins of mammalian or viral origin, with very large proteins or with 
proteins containing disulfide bonds, expression levels are often very low [2, 3]. 
Expression of transmembrane proteins is even more challenging due to low expression 
levels, a high tendency to aggregate in inclusion bodies, cellular toxicity and plasmid 
instability [4]. In such cases, expression has to be optimised thoughtfully to minimize 
efforts in subsequent large scale purification steps. Usually this is performed by stepwise 
testing of different vector systems, bacterial hosts, media, as well as the expression 
conditions itself, e.g., temperature, IPTG concentrations and time point of induction [5]. 
In this study a single assay is described that allows simultaneous screening for optimal 
expression parameters and its efficacy was demonstrated on two retroviral 
transmembrane envelope (TM) proteins that are difficult to express.  
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The TM proteins of retroviruses are essential for infection and have been well 
investigated in the case of the human immunodeficiency virus type 1 (HIV-1) and murine 
leukaemia virus (MuLV). They consist of a hydrophobic N-terminal fusion peptide, N-
and C-terminal alpha helical regions connected through a cysteine loop, and the 
membrane spanning domain anchoring the protein in the viral membrane. After insertion 
of the fusion peptide into the cellular membrane, conformational changes and hairpin 
formation allow infection of the cell [6]. Foamy viruses are retroviruses belonging to the 
subfamily Spumaretrovirinae [7, 8]. Due to their large packaging capacity and broad 
tissue tropism they are of interest as vectors for gene therapy and vaccine applications [9-
11]. The envelope (Env) proteins of the foamy viruses differ in numerous points from 
those of other retroviruses. They consist of the Env leader protein (Elp) [12], the surface 
envelope protein and the TM protein [13]. The TM proteins are larger, their central part is 
characterised by the presence of seven to eight cysteines and numerous potential 
glycosylation sites [14, 15] and electron microscopic pictures demonstrate an unusual 
trimeric oligomerisation [16]. Recently the TM protein of the feline foamy virus (FFV) 
was produced and used for serological screening of infections in cats and for 
immunisation studies [17]. When compared with diagnostic methods based on the 
detection of antibodies against Gag, detection of antibodies against the TM protein was 
found to be a reliable diagnostic tool [17, 18]. In this report, an improved protocol for the 
expression and purification of this protein as well as for the TM protein of the primate 
foamy virus (PFV)is described. Since we encountered extreme difficulties producing this 
protein in the beginning, a small scale expression screen based on 96 deep well plates 
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was developed, which proved to be very powerful and allowed optimisation of expression 
conditions in less than two days.  
 
Material and methods 
 
Construction of expression plasmids 
The sequence of the ectodomain of the PFV TM protein (ENV-SFVcpz(hu), Uniprot Acc. 
Nr. P14351, AS 600-961) was amplified by proof-reading PCR using the plasmid 
pHSRV13 [19] and the primers PFV-ED-Xa 5’-
aggatctggctctggatctggtatcgagggaagggatattaatgatgaaaactta-3’ and PFV-ED rev 5’-
atactcgagttagtgatggtgatggtgatggtggtgaggctttaagtatcccaagag-3’. The amplicon was 
subsequently cloned into prokaryotic expression vector pGEX-KG [20] digested by 
SmaI/XhoI to yield the expression plasmid pGEX-PFV-ED. Similarly, the expression 
plasmid pGEX-FFV-TMop, containing the codon-optimised sequence of the ectodomain 
of the TM protein of FFV (ENV-FFV, Uniprot Acc. Nr. O56861, amino acids 563-944) 
was obtained by cloning the corresponding PCR fragment into pGEX-KG using the 
following primers: FFV-TMop-Xa 5’-aggatctggctctggatctggtatcgagggaagggatctg-
aacgatcagaaactg-3’ and FFV-TMop-rev 5’-atactcgagttagtgatggtgatggtgatggtg-
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Small scale expression and solubility testing 
Initial expression experiments were performed in E.coli BL21. After transformation, five 
ml LB-Medium were inoculated with single colonies from LB plates and grown 
overnight. Cultures were diluted in 20 ml fresh LB media to obtain an OD600 of 0.1 and 
incubated at 37 °C for 3 h. One ml of non-induced cells was taken for SDS PAGE 
analysis. Expression was induced by addition of 1 mM isopropyl-β-D-
thiogalactopyranosid (IPTG), cells were incubated for 3 h at 37 °C and 1 ml of induced 
cells collected. After pelleting (10.000 g, 10 min), remaining cells were lysed in PBS, 0.1 
mg/ml lysozyme, 50 U/ml benzonase for 15 min on ice and subsequently sonicated for 3x 
20 s using a Branson sonicator equipped with a microtip. Total lysates were collected 
before separation of soluble and insoluble material by centrifugation (16.000 g, 30 min). 
The supernatants were saved and pellets were resuspended in equal volumes of PBS with 
lysozyme. Total lysate, supernatants and pellets were analysed by SDS PAGE.  
 
Expression screening in 96 deep well plates 
To optimise expression conditions, the parental pGEX-KG vector and expression 
constructs were transformed into E. coli SHuffle T7 Express (NEB), C43 (Lucigen), 
SCS-1/pSE111 (Stratagene) and Rosetta 2 (Novagen). From each plate, two colonies of 
different size were selected and grown as day cultures until an OD600 of 0.6 and stored as 
glycerol stocks. From these stocks overnight cultures were grown in LB medium 
containing appropriate antibiotics. On the next day, each well of a 96 deep well plate 
containing one millilitre of either LB (10 g tryptone, 5 g yeast extract, 170 mM NaCl, pH 
7.5), 2YT (16 g tryptone, 10 g yeast extract, 100 mM NaCl, pH 7.4) or TB medium (12 g 
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tryptone, 10 g yeast extract, 0.4 % glycerol, 15 mM KH2PO4 pH 7.4) and appropriate 
antibiotics was inoculated with 100 µl of the stationary overnight culture adjusted to an 
OD600 of 2.0 and grown for three hours at 37 °C. For induction of protein expression, 
cultures were adjusted to 0.1 and 1 mM IPTG in parallel to non-induced controls. Empty 
control vectors were induced with the highest IPTG concentration only. After additional 
three hours incubation at the indicated temperatures, cells were pelleted by centrifugation 
for 15 min at 3700 rpm in an Eppendorf plate centrifuge, lysed by three successive 
freeze/thaw cycles in liquid nitrogen and subsequently resuspended in 100 µl lysis buffer 
(PBS, 0.1 mg/ml lysozyme, 50 U/ml benzonase). For expression analysis 10 µl of the 
total cell lysate were boiled in SDS sample buffer and analysed by SDS-PAGE in a HT-
PAGE System (CBS Scientific) and Coomassie blue staining. 
 
Large scale production 
For production of milligram quantities of the fusion proteins, optimised conditions from 
the previous small scale screen were scaled up accordingly. pGEX-FFV-TMop and 
pGEX-PFV-ED constructs were grown in the BL21 Rosetta 2 host and 1 litre TB-
Medium per 5 litre baffled flask at 37 °C until an OD600 of 0.8, followed by induction 
with 1 mM IPTG. After three hours of induction, cells were pelleted by centrifugation 
and stored at -20 °C until purification.  
 
Large-scale cell lysis and protein purification 
Cell pellets were resuspended in lysis buffer 2 (20 ml/g cell pellet, PBS, 1 mg/ml 
lysozyme, Complete protease inhibitor) and incubated for 15 minutes on ice. The 
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suspension was sonicated three times for 20 s and cell debris was removed by low speed 
centrifugation (480 g, 10 min). Supernatants were subjected to another centrifugation step 
at 25.000 g (1 hour, 4 °C) and pellets were extracted with lysis buffer 2 containing 1% 
sarkosyl (N-lauroylsarcosine, Sigma Aldrich, Germany) for one hour at 4 °C under 
shaking. Solubilised proteins were separated from remaining insoluble material by 
centrifugation (10.000 g, 10 min) and diluted 1:10 with wash buffer (PBS, 0.1% sarkosyl, 
20 mM imidazol, pH 7.5) before loading on HisTrapFF crude NiNTA affinity columns 
installed in an Äkta-Explorer 10s FPLC system (all GE Healthcare, Germany). The 
columns were washed intensively with washing buffer until an OD280 below 0.01 
absorption units and eluted using a 20 column volumes gradient with elution buffer (PBS, 
0.1% sarkosyl, 500 mM imidazol, pH 7.5). Protein concentration was estimated by 
absorption at 280 nm using calculated molar extinction coefficients of ε=1.561, 1.488, 
1.550 and 1.399 L/mol*cm for the glutathion-S-transferase (GST) fusion proteins of the 
TM proteins of FFV and PFV or the cleaved TM proteins of FFV and PFV, respectively. 
 
Glutathion S-transferase (GST) assay  
The GST activity of bacterial lysates or purified GST fusion proteins was analysed using 
CDNB (1-chloro-2,4-dinitrobenzene, Sigma-Aldrich). The colorimetric GS-DNB 
conjugate was detected at 340 nm using a Tecan Reader and 96 well plates (Nunc). 
Samples were measured in one minute intervals for 10 minutes. after addition of 100 µl 
substrate solution, which was freshly prepared using 94 µl CDNB dilution buffer (100 
mM sodium phosphate buffer, 1 mM EDTA, pH 6.5), 3 µl CDNB substrate solution (30 
mM CDNB substrate in 95% ethanol) and 3 µl CDNB glutathione solution C (75 mM 
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reduced glutathione in CDNB dilution buffer) per well. All measurements were 
performed in triplicates.  
 
Removal of GST by protease treatment 
To remove the GST moiety, purified proteins with concentrations of at least 0.5 µg/µl 
were cleaved with thrombin protease (Sigma-Aldrich) at a ratio of 12.5 units protease per 
milligram protein for three hours at 37 °C under gently shaking. To remove thrombin 
protease and released GST, the digestion mixture was diluted 1:10 with wash buffer and 




The GST fusion proteins of the TM protein of FFV and PFV, purified by NI-NTA 
affinity purification, were subjected to gel filtration in a Superdex 200 10/300 GL column 
(GE Healthcare, Germany) equilibrated with gel filtration buffer (PBS, 0.1% sarkosyl, 
pH 7.5) and eluted isocratically with a flow rate of 0.4 ml/min for 1.2 column volumes. 
Main peaks of the obtained chromatogram were analysed by SDS PAGE and Coomassie 
blue staining. Protease treated proteins were analysed on a gel filtration buffer 
equilibrated Superdex 75 10/300 GL column (GE Healthcare) at flow rates of 0.4 ml/min. 
For CD measurements buffer exchange was performed by loading proteins onto Superdex 
200 10/300 columns equilibrated with 10 mM NaH2PO4, 0.02 % (w/v) n-dodecyl-beta-D-
maltoside, pH 7.5 and if necessary concentrated with Vivaspin 6 columns with a MWCO 
of 5 kDa, Sartorius, Germany) 
  
  10 
CD spectroscopy 
Purified proteins were measured in a Jasco 720 spectropolarimeter in 0.01 cm quartz 
cuvettes with 0.1 nm dot pitch and 50 nm/min scanning speed in the range of 260-190 
nm. Ellipticity θ was calculated with obtained CD data in millidegrees, mean residue 
weights of 114.4, 111.3, 113.5 and 111.9 g/mol and protein concentrations of 0.21, 0.28, 
0.20 and 0.27 mg/ml for the GST-TM and TM proteins of FFV, and the GST-TM and 
TM proteins of PFV, respectively. Spectra are means of ten individual measurements 
performed at room temperature subtracted by the mean spectrum obtained with buffer. 
For estimation of secondary structures, CD data were analysed with SELCON3, 
CDSSTR and CONTINLL programs which are part of the CDpro software package [21, 
22] using the SMP56 protein reference set which includes spectra of 40 soluble and 13 
membrane proteins and which is optimised for interpretation of spectra in the range of 
190-240 nm [23, 24]. Amino acid based secondary structure predictions were obtained 
with the PROFsec algorithm included in the PredictProtein package [25]. 
ELISA 
Recombinant antigens were purified either by the urea/on-column refolding 
protocol or by the sarkosyl extraction method, diluted in distilled water and coated 
overnight at 37°C to 96 well plates (200 ng per well). After washing once with PBS-T 
(phosphate buffered saline, 0.05% Tween 20) and blocking with blocking buffer (1% 
non-fat dry milk in PBS-T), triplicates of sera diluted 1:100 in blocking buffer were 
added to the wells and incubated for one hour at 37oC. After washing three times with 
PBS-T, HRP (horseradish peroxidase)-conjugated anti-cat IgG antibody (Bethyl 
Laboratories, dilution 1:3000) was added for one hour at 37°C and plates then washed 
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seven times using PBS-T. Detection was performed using OPD (o-phenylenediamine 
dihydrochloride) substrate dissolved in PBS containing hydrogen peroxide and the 
absorbance was measured at 492 nm and 620 nm after 10 minutes of incubation. As 
controls a TM protein specific antiserum (goat serum 348, [17]) and the secondary 
antibody were used. Cut offs were calculated as the mean absorbance of 14 included 
negative sera plus 2.743 times the mean standard deviation corresponding to a statistical 
confidence level of 99% [26]. Absolute cut off values were 211 mAU and 207 mAU for 




Cloning strategy and expression plasmids 
In first attempts to express the TM proteins of FFV and PFV, plasmid constructs were 
generated by cloning the TM ectodomain lacking the fusion peptide but containing either 
an N-terminal GST or His-tag. Using GST tagged proteins, only very low (PFV) or 
absence (FFV) of expression of the TM protein was observed (data not shown). Both 
recombinant proteins were highly insoluble that prevented purification using glutathione 
sepharose. Furthermore, numerous breakdown products were found. When the proteins 
were expressed with an N-terminal His-Tag, expression was very low and detectable only 
by Western blot analysis, indicating that the GST fusion partner contributed to an 
increased expression (data not shown). To employ the advantages of both tags, constructs 
with an N-terminal GST-tag and a C-terminal His-tag were generated (Fig. 1). In case of 
the TM protein of FFV, a codon-optimised sequence was used to enhance expression in 
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E. coli. This construct showed a fivefold increased expression compared to the non-
codon-optimised sequence (not shown). To allow removal of the GST moiety either the 
thrombin cleavage site encoded by the vector could be used or an additional factor Xa 
cleavage site was introduced by PCR (Fig. 1A). Whereas thrombin cleavage resulted in 
recombinant proteins containing twelve vector-derived amino acids, factor Xa digestion 
allows removal of all unrelated amino acids (Fig. 1A). A schematic presentation of the 
TM proteins of FFV and PFV and the produced recombinant proteins is given in Fig. 1B. 
 
Small scale expression and expression optimisation 
Similar to the findings of the first expression constructs, both double tagged proteins 
were also poorly expressed and insoluble in E. coli BL21 under standard expression 
conditions (Fig. S1). To improve expression levels and solubility, different bacterial host, 
media, temperature, and inducer concentrations were tested. The 96 deep-well format 
offered best opportunities to analyse all conditions in parallel (Fig. 2). In addition, the 
plate layout allowed direct transfer of lysates to SDS PAGE using multichannel pipettes. 
Prior to screening, plasmid constructs were transformed into four specialised E. coli 
strains with various genetic backgrounds, chosen to fit the particular properties of both 
proteins: Shuffle T7 Express cells have been designed for proteins containing cysteines 
residues allowing formation of disulfide bonds in the cytosol of E.coli by overexpression 
of the cytoplasmic disulfide isomerase DsbC  [27, 28], C43 cells contain an 
uncharacterised mutation compensating for expression of toxic and particular membrane 
proteins [4, 29], SCS-1/pSE111 cells are K12 derivatives containing the pSE111 plasmid 
supplying arginine t-RNAs for improved expression of eukaryotic proteins. Similarly, the 
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Rosetta 2 strain supplies tRNAs of seven codons rarely produced in E.coli but has the 
genetic background of the BL21 strain [30]. Since protein expression may vary 
significantly between individual transformants [31], two clones were selected for analysis 
together with the parental GST expressing vector as control. In addition, the influence of 
the media, either standard LB medium, enriched 2YT medium or terrific broth (TB) was 
tested. Solubility of recombinant proteins often increases when expression levels were 
reduced, either due to a slower error rate during translation or prolonged time for 
refolding processes resulting in a lower probability of aggregate formation [32]. Thus, 
expression at two IPTG concentrations and a non-induced control at temperatures of 16 
°C and 37 °C were tested. Since protein expression was nearly identical at both 
temperatures (not shown), only results obtained at 37 °C are presented here (Fig. 3). In 
case of the PFV-TM protein, good expression levels were achieved in three of the four 
bacterial hosts tested (Shuffle T7, SCS-1, Rosetta 2) but only weak expression was 
obtained in the C43 host (Fig. 4A). Minor differences in the expression levels were found 
when three different media and individual transformants were compared (Fig. 3A, lane 
LB, 2YT, TB and lane TM1 and TM2, respectively). However, as expected, expression 
increased at higher IPTG concentrations (0.1 to 1 mM, Fig. 3A). In the case of the TM 
protein of FFV, more striking differences were found when the various conditions were 
compared. Three of the four bacterial strains (Shuffle T7, C43, Rosetta 2) showed high 
expression levels, whereas no recombinant protein was produced in the SCS-1/pSE111 
K12 derivative (Fig. 3B). Importantly, in the three expression strains tested, only bacteria 
grown in TB medium produced satisfactory amounts of protein, suggesting a highly 
advantageous role of glycerol as an additional carbon source. Production yields were 
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doubled by increasing IPTG concentrations from 0.1 to 1 mM (Fig. 3B). No differences 
were observed when two different clones were compared (Fig. 3B, TM1 and TM2). Even 
under mild expression conditions (16°C and 0.1 mM IPTG) only small amounts (PFV) or 
no TM protein (FFV) were found in the supernatant (Fig. S2), indicating that despite 
different levels of expression, none of the bacterial strains or growth conditions had a 
beneficial effect on protein solubility.  
 
Detergent screening 
To increase protein solubility during the purification process, various detergents were 
analysed for their ability to solubilise both proteins from the insoluble fraction. Whereas 
strong anionic detergents were as expected very efficient, none of the tested non-ionic 
detergents except Brij35 (10%) allowed solubilisation of the proteins (Fig. S3). However, 
binding to glutathione sepharose as well as the enzymatic activity of GST using CDNB as 
substrate were disturbed under these conditions (data not shown). Addition of the same 
detergents including Brij35 during cell lysis did also not increase solubility (not shown). 
Adopting a protocol described for the purification of insoluble actin [33], sarkosyl was 
added during bacterial lysis to prevent precipitation of the TM proteins. Although this 
approach brought about 50% enzymatically active GST-TM proteins into solution at a 
concentration of 0.3% (w/v) sarkosyl (the critical micelle concentration is 0.4% w/v), 
GST activity was not longer detected when affinity purified proteins were measured in 
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Large scale production and purification 
Since the highest expression levels of both proteins with the lowest amounts of 
background proteins were observed when the Rosetta 2 strain and TB media were used, 
these conditions were selected for large scale production of both proteins. Although 
altered aeration conditions in cultures without external oxygen supply, loss of expression 
plasmids or reduction of the pH due to cell metabolites have been described to reduce 
protein yields when scaling-up small scale experiments [3, 34], such negative effects 
were not observed when both TM proteins were produced using Rosetta 2 cells and the 
optimised conditions. Since attempts to purify both proteins under non-denaturing 
conditions failed, a denaturing purification strategy was applied. Both GST-fusion 
proteins were extracted from the insoluble fraction by incubation with 1% sarkosyl 
followed by a subsequent refolding step by dilution of the lysate before affinity 
purification (see Material and methods). Using this purification protocol the protein 
yields of the TM protein of FFV was drastically improved from about 0.5-0.8 mg/l 
originally obtained with the previously described on-column refolding protocol [17] up to 
14-16 mg/l (Table 1). The protein yields obtained for the TM protein of PFV were in the 
same range (15-18 mg/l, Table 1). The sarkosyl purification protocol was less efficient 
concerning purity when compared to the urea/on-column refolding protocol (95% 
compared to 90% purity, Table 1). This lower purity is attributed to two proteins 
migrating at 42 and 34 kDa which were commonly detected by SDS-PAGE (Fig. 4A and 
B, lane IN). Since these proteins were also detected by anti-His antibodies (not shown), 
they probably represent breakdown products of the TM proteins lacking the GST or GST 
and linker residues. The addition of protease inhibitors during lysis did not prevent their 
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occurrence; therefore, they might be a result of instability at the flexible linker amino 
acids located between GST and the TM proteins.  
 
Analysis of protein aggregation 
To analyse the aggregation state of the purified proteins, protein samples from affinity 
purification steps were subjected to gel filtration (Fig 4). For the TM protein of FFV the 
chromatogram showed a prominent peak at 10.05 ml and two smaller peaks eluting at 
11.95 ml and 13.8 ml (Fig. 4A). SDS PAGE analysis of the elution fractions showed the 
GST TM protein of FFV with the expected molecular weight of 68 kDa and small 
amounts of higher molecular weight aggregates migrating at 130 kDa, 200 kDa and some 
close to the void volume (Fig. 4 inset). In the residual fractions, breakdown proteins with 
the molecular weights of 42 and 34 kDa were found (Fig. 4A, lanes 5-7). For the TM 
protein of PFV the elution patterns were similar (Fig. 4B), however, this protein showed 
a higher tendency to aggregate and to form multimeric species at 130 and 200 kDa 
compared to the FFV GST TM protein (compare lanes 2 of Fig 4 A and B). These results 
indicate that most of the sarkosyl extracted GST TM proteins were in a non-aggregated, 
monomeric form. 
 
Removal of the GST fusion by protease treatment 
To obtain proteins lacking the GST residue, proteins purified by gel filtration (Fig. 5A 
and B, lane E) were treated with either factor Xa or thrombin protease. Whereas removal 
of GST by factor Xa digestion resulted in incomplete cleavage at high enzyme 
concentrations and prolonged incubation times (data not shown), cleavage with thrombin 
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at 12.5 units per milligram protein (ratio 1:80) achieved complete digestion within three 
hours. After an additional affinity purification step, pure TM proteins of FFV and PFV 
with minor degradation products were obtained (Fig. 5A and B, lane ET). Gel filtration of 
these proteins confirmed that they were predominantly non-aggregated (Fig. 6).   
 
Secondary structure analysis using CD spectroscopy 
To assess the secondary structures, proteins were analysed by CD spectroscopy and the 
results were compared to secondary structure predictions obtained by bioinformatic 
analysis. Sarkosyl is strongly absorbing at wavelengths below 220 nm and thus had to be 
replaced by a non-interfering detergent for this purpose. By testing CD spectroscopy 
compatible detergents, n-dodecyl-ß-maltoside (DDM) was found not to allow aggregation 
(data not shown). The buffer was exchanged by gel filtration and spectra were measured 
at wavelengths of 260-195 nm (Fig. 7). Typical pattern of alpha helical secondary 
structures with the characteristic plateaus at 222 and 208 nm and increased ellipticity at 
195 nm [35] were found. When proteins with and without the GST fusion part were 
measured, only minor differences were found (Fig. 7A and B, solid and dashed lines). 
However, the TM proteins of FFV and PFV varied slightly, in particular at 215-208 nm, 
were negative ellipticity values were much more pronounced for the TM protein of FFV. 
By extracting the structural data from the measured spectra by fitting algorithms included 
in the CDpro software package and the SMP56 reference spectra, CONTINLL provided 
the closest approximation to the measured spectra. When these results were compared to 
amino acid based predictions (Table 2), a good correlation was found.  
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Screening for FFV infection using proteins from both purification protocols 
To compare the ability to detect antibodies in sera of infected cats using the TM protein 
of FFV purified by the sarkosyl extraction method with that obtained by on-column 
refolding as used recently,[17], a comparative ELISA was performed. 30 sera with 
known FFV serological status (16 positive, 14 negative as determined previously by 
ELISA using Gag, Bet and TM proteins and immunoblots using infected CRFK cells [17, 
18]) were selected for this screening. Both ELISA detected 16 of the 16 FFV positive 
sera (Fig 8)., indicating that both proteins were equally suitable for serological screening.  
 
Discussion 
In the present study, an improved protocol for the expression and purification of the large 
TM proteins of two retroviruses of the Spumaretrovirinae sub-family, PFV and FFV, is 
described. Using a screening method based on 96 deep well plates for optimisation, 
optimal expression conditions were rapidly determined and transferred to large scale. By 
optimisation of expression and the use of a detergent based purification protocol, yields 
of both TM proteins were increased to 14 to 18 mg protein per litre with purity about 
95%. Gel filtration and circular dichroism experiments showed that the obtained proteins 
were predominantly non-aggregated and possessed defined secondary structures. In case 
of the TM protein of the FFV the protein purified by this means was found to be similarly 
suitable to detect FFV infection as the FFV TM antigen described previously [17]. In 
case of the PFV TM protein, immunisation experiments have been performed and an 
ELISA for the detection of PFV infection is currently under development. 
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To obtain sufficient amounts of the TM proteins of PFV and FFV, several 
expression parameters were investigated. Although both TM proteins are closely related, 
remarkable differences in production were found. Among all parameters tested, the E. 
coli producer cell and the growth medium had the strongest influence on the expression 
levels. In terms of the bacterial host used, expression seemed to follow an ‘all or nothing’ 
principle: whereas the differences in expression levels in producing bacteria were 
neglectable, other bacteria did not produce the protein even when the expression 
parameters were varied (Fig. 3). For both TM proteins, the bacterial strains Shuffle T7 
and Rosetta 2 were most suitable, possibly due to improved disulfide binding (Shuffle 
T7) and supplementation of seven t-RNAs (Rosetta 2). However, in case of the TM 
protein of FFV this result is somewhat unexpected since the sequence was codon-
optimised. Interestingly, only one medium, Terrific broth (TB) medium, which contains 
glycerol as additional carbon source, supported the production of the TM protein of FFV 
(Fig. 3).  
In contrast to expression experiments in E. coli at high cell density [31], there 
were no significant differences between individual transformants selected for screening. 
As a consequence, future screening could be modified by including additional vectors 
carrying other fusion partners (e.g. maltose binding protein (MBP), NusA, thioredoxin) 
instead of analysis of different clones. A strong influence of the fusion partner on protein 
expression and solubility has been described repeatedly [36-38]. In order to facilitate 
testing for solubility of the produced protein, an additional centrifugation step using filter 
plates or an ultracentrifugation step using 96 well plates may also be included to remove 
insoluble material [38-40]. 
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Selection of different bacterial host cells and changing growth temperature or 
IPTG concentrations did not have any effect on protein solubility. This surely can be 
attributed to the nature of the proteins expressed here, two retroviral TM proteins. 
Although only the ectodomains of the TM proteins lacking the hydrophobic fusion 
peptide and the membrane spanning domain were expressed, the proteins were insoluble. 
This may be explained by the interaction of the two helical regions which are naturally 
interacting during infection resulting in a six-helix-bundle formation. However, the 
extreme insolubility of the TM proteins of the FV is in contrast to solubility of the TM 
proteins of different gammaretroviruses also expressed in E.coli. As was shown for the 
porcine endogenous retrovirus (PERV) [41], the feline leukaemia virus (FeLV) [42] and 
the Koala virus (KoRV) [43] these proteins were partly soluble and were successfully 
used for induction of neutralising antibodies and serological testing. p15E of PERV is 
now part of a newly developed assay to screen animals and human recipients for 
transmission of PERV during experimental and clinical xenotransplantation [44, 45]. The 
TM proteins of the gammaretroviruses are small (15 kDa) and non-glycosylated, whereas 
the TM proteins of the foamy viruses are much larger (gp48), they contain seven to eight 
cysteines and are highly glycosylated [15]. This resembles the situation described for the 
lentiviral TM proteins of HIV-1 (gp41) and HIV-2 (gp36), which are also not soluble in 
aqueous solutions (our own unpublished observations and [46]).  
Both TM proteins could be partially resolubilised at detergent concentrations 
known to preserve biological function of proteins [47]. Although the GST activity could 
be measured under these conditions in cell lysates, the purified proteins did loose their 
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activity after affinity purification. This is possibly due to the high protein concentration 
during elution and may be prevented by different buffer conditions.  
 The conformation of the TM proteins is important for their application in 
diagnostic assays as well as in immunisation studies. Proteins obtained with the method 
described here were sufficient for screening for FFV infection in cats using ELISA and 
Western blot analyses (Fig. 8). Although the purification protocol used here differs from 
the previous one using denaturing conditions followed by an on-column refolding step 
[17] no differences in the ELISA performance were observed (Fig. 8). Together with the 
results from CD spectroscopy (Fig. 7) and bioinformatic predictions (Table 2), this 
suggests that essential structural elements necessary for antibody recognition in sera of 
infected cats were restored by the dilution-refolding protocol applied here. 
Despite this, immunisation studies using purified TM proteins of both foamy 
viruses as a potential vaccine antigen were not successful and although high titres of 
binding antibodies were induced, they were not able to neutralise FFV or PFV ([17] and 
unpublished). Whereas induction of neutralising antibodies immunising with the 
ectodomain of the TM protein of gammaretroviruses was easily achieved [41-43] all 
attempts to obtain such antibodies for HIV-1 and HIV-2 using similar proteins also failed 
[46, 48]. As already pointed out, the TM proteins of the gammaretroviruses are rather 
small and not glycosylated, whereas the TM proteins of HIV-1, HIV-2, FFV and PFV are 
heavily glycosylated and stabilised by cysteine bridges. The influence of different 
parameters on the conformation of the TM proteins of the lenti- and spumaviruses and 
their ability to induce neutralising antibodies is largely unknown, and it is unclear 
whether glycosylation may contribute to generate a suitable conformation for the 
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induction of neutralising antibodies. Comparative structural, functional, and 
immunological studies using small (gammaretroviruses) and large (lenti- and foamy 
viruses) TM proteins of distantly related retroviruses may allow defining common and 
unique requirements for protein production and purification and may thus offer the 
chance for designing novel candidate vaccines against retroviruses including HIV-1.    
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Figure Legends 
 
Fig. 1. Schematic presentation of expression constructs. (A) Parental expression vector 
pGEX-KG and the applied cloning strategy. pGEX-KG was digested with SmaI/XhoI and 
PCR amplicons coding for the ectodomain of the TM proteins of FFV (in this case codon-
optimized) or PFV were ligated into the linearised vector. In addition, an N-terminal 
Factor-Xa cleavage site and a C-terminal His-Tag (not shown) were introduced. (B) 
Structural features of the FV envelope proteins and presentation of resulting recombinant 
proteins. ELP - envelope leader peptide, SU - surface envelope protein, FP - fusion 
peptide, TM - transmembrane envelope protein, MSD – membrane spanning domain. The 
black arrows indicate furin cleavage sites. Amino acid numbering is corresponding to 
Uniprot entry O56861 for FFV and Q87041 for PFV, respectively. The theoretical 
molecular weights are indicated on the right. 
 
Fig. 2. Strategy to optimise protein expression in 96 deep well plates. Four bacterial 
strains (strain 1-4), three growth media (M1, M2, M3), three IPTG concentrations (grey 
arrows) and two transformants (clone 1, clone 2) along with the empty vector as control 
were used. One plate was used for every temperature to be investigated. This design 
allowed easy transfer to subsequent SDS PAGE analysis by multichannel pipettes. 
 
Fig. 3. Influence of the expression conditions on protein production. Bacterial strains 
SHuffle T7, C43, SCS-1, and Rosetta 2 were transformed with the expression constructs 
of the TM proteins of FFV and PFV and two transformants (TM1, TM2) along with the 
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empty expression vector (KG) were grown in different media (LB, 2YT, TB). Expression 
was induced with increasing concentrations of IPTG (grey arrows, corresponding to 0, 
0.1 and 1 mM IPTG). Recombinant proteins and GST from the parental vector are 
indicated by black arrows.  
 
Fig. 4. Gelfiltration of the affinity purified TM protein of FFV (A) and that of PFV (B). 
Separations were performed on a Superdex 200 10/300 GL column with PBS, 0.1 % 
sarkosyl at 0.4 ml/min. Inset: Analysis of elution fractions 1-7 by SDS PAGE along with 
a sample of material loaded on the column (IN). Numbers on the right indicate molecular 
weights, Vo – dead volume of the column. 
 
Fig. 5. Expression of the TM protein of FFV (A) and that of PFV (B) under non-
optimised and optimised conditions and their purification. Lane M, molecular weight 
marker; L, non-induced lysate; IL, induced lysate; E, elution fraction of the GST fusion 
protein after gel filtration, ET, elution fraction of the TM protein after thrombin digestion.  
 
Fig. 6. Analytical gel filtration of the thrombin treated TM protein of FFV (A) and that of 
PFV (B). Proteins were analysed on a Superdex 75 column in PBS, 0.1 % sarkosyl at a 
flow rate of 0.4 ml/min (black solid lines). Ovalbumin with a molecular weight of 43 kDa 
was run under identical conditions as molecular weight marker (grey dashed line).  
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Fig. 7. Circular dichroism analysis of the purified GST TM fusion protein (grey dashed 
line) and the TM protein (black solid line) of FFV (A) and PFV (B). The were analysed 
in a Jasco 720 spectropolarimeter at wavelengths of 260-195 nm.  
 
Fig. 8. Comparative ELISA of proteins purified by an urea/on column refolding (black 
bars) or the sarkosyl extraction method (grey bars). The GST TM fusion protein of FFV 
purified by both protocols were coated on ELISA plates and incubated with cat sera of 
known serological FFV infection status. 
 
Fig. S1. Expression levels and solubility of the TM proteins of FFV (A) and PFV (B) 
produced under non-optimised conditions in BL21 cells, L, lysate without inducer, IL+, 
induced lysate, SN, supernatant; P pellet. In the Western blot (WB) analysis antibodies 
against the His tag were used. The TM protein is marked by an arrow. 
 
Fig. S2. Expression levels and solubility of the TM proteins of FFV (A) and PFV (B) 
produced under different conditions in different bacteria, L, lysate without inducer, IL, 
induced lysate, SN, supernatant; P pellet. In the Western blot (WB) analysis antibodies 
against the His tag were used. The TM protein is marked by an arrow. 
 
Fig. S3. Solubilisation of the TM protein of FFV using various detergents. (A) Producing 
cells were lysed with PBS, lysozyme and cell debris were removed by low speed 
centrifugation (TL, total lysate). The supernatants were split in one millilitre fractions and 
centrifuged for one hour at 16.000 g (SN, supernatant; IP, insoluble pellet (IP). The other 
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pellets were extracted with 1 or 10% of the indicated detergents (SY, sarkosyl, NP, NP-
40, TX, Triton-X 100, TW, Tween 20, OG, OG-beta, DM, dodecylmaltoside, CH, 
CHAPS, B35, Brij35, Mix, sarkosyl, CHAPS, Triton-X 100) for three hours at room 
temperature and centrifuged at high speed for thirty minutes and the supernatants were 
loaded. The TM protein of FFV is indicated by an arrow; in the Western blot analysis an 
antiserum against GST was used. 
 
Fig. S4. Influence of sarkosyl on solubility (A) and enzymatic activity (B) of the GST 
TM fusion protein of PFV. (A) Pellets from TM protein producer cells were incubated 
with PBS containing lysozyme (0.1 mg/ml) on ice for 15 minutes, 5 mM DTT and the 
indicated amount of sarkosyl were added, after sonification for 3x10 s and 10 minutes 
rotation at room temperature the total lysates (TL) were centrifuged for 10 minutes at 
10.000 g to separate supernatants (SN) and pellet (P). GST TM fusion protein of PFV is 
marked by an arrow. (B) Kinetics of the GST activity of each sample shown in (A), 
purified GST (0.176 ug/ml) was used as control. The red line marks 10 min incubation 
(C) GST activity at 10 minutes as shown in (B). The red circle marks the concentration 




Table 1 Comparison of purity and yields using two different purification protocols (AC = affinity chromatography).  
 
  Urea protocol   Sarkosyl protocol  
 FFV TM FFV TM PFV TM 
 Purity Yield Purity Yield  Purity Yield
 
AC and on-column refolding 95 % 0.5-0.8 mg/l   -       -     -    - 
Rapid dilution refolding and AC   -   -  90 % 14-16 mg/l 90 % 15-18 mg/l 
Gel filtration     -      - 95 % 12-14 mg/l 95% 13-16 mg/l 
 
  
Table 2. Comparison of predicted and measured secondary structure contents in purified foamy virus proteins. 
              Predictions          CD-Measurements    
-helical  -sheets  coiled    -helical  -sheets  coiled 
FFV GST TM    43.6     15.2     41.2     37.5     15.1     47.5   
FFV TM    39.2     22.2     38.7     41.1     12.2     46.6  
PFV GST TM    45.8     14.2     39.9     37.9     16.0     46.3 
PFV TM    41.8     20.7     37.5     37.0     15.9     47.2  
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Highlights 
- Expression and purification of the transmembrane envelope proteins of foamy viruses 
-  Screening assay for optimisation of expression in 96 deep well plates 
- Characterisation of purified proteins by gel filtration and circular dichroism  
- Application in immunological assays screening for foamy virus infection  
 
 
